ReNeuron upbeat on data around ease of exosome manufacture

The AIM-traded firm said Dr Nicola Goddard of the Department of Biochemical Engineering at University College London would present the new data from a grant-funded collaboration between ReNeuron, UCL and the Cell and Gene Therapy Catapult, at the ECI Advancing Manufacture of Cell and Gene Therapies VI conference in Coronado, California.

It said the new data demonstrated the feasibility of scaling-up the production of ReNeuron's CTX-derived exosomes utilising “state-of-the-art” bioreactor systems, representing a “significant advance” towards an industrial scale production process without affecting the quality and consistency of the final product.

The ongoing collaboration was part-funded by a grant from Innovate UK.

“Exosomes are biological nanoparticles ideally suited to the delivery of oligonucleotide and gene-based therapies due to their natural occurrence and abundance, their ability to protect their cargo from degradation, and their potential for favourable bio-distribution,” said ReNeuron head of research, Dr Randolph Corteling.

“The ability to scale-up production of our CTX-derived exosomes, as demonstrated by these new results, further exemplifies the capability of ReNeuron's exosome platform.”